Talacotuzumab-MMAE, an antibody-drug conjugate (ADC), combines an IL-3Ralpha-targeting antibody with Monomethyl auristatin E (MMAE) and is utilized in acute myeloid leukemia research.
Target:
IL Receptor
* VAT and and shipping costs not included. Errors and price changes excepted
